Published in Blood Transfus on July 01, 2010
Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. Blood Transfus (2011) 1.14
Perioperative neonatal and paediatric blood transfusion. Indian J Anaesth (2014) 1.08
Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease. Mol Cell Proteomics (2012) 0.97
Transfusion and coagulation management in liver transplantation. World J Gastroenterol (2014) 0.92
Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Crit Care (2016) 0.90
Clinical use and the Italian demand for prothrombin complex concentrates. Blood Transfus (2013) 0.83
Budget impact analysis of warfarin reversal therapies among hip fracture patients in Finland. Drugs R D (2015) 0.82
Reversal of oral anticoagulation. Pharmacotherapy (2013) 0.82
Hemostasis in liver transplantation: Pathophysiology, monitoring, and treatment. World J Gastroenterol (2016) 0.81
Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients. Crit Care (2014) 0.80
Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial. BMC Surg (2013) 0.79
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Crit Care (2016) 0.76
Appropriate timing to start and optimal response evaluation of high-dose corticosteroid therapy for patients with acute liver failure. J Gastroenterol (2017) 0.75
Managing a Rivaroxaban Bleed: Understanding the Difficulties in Acute Reversal of the New Oral Anticoagulants through a Case Report. Case Rep Hematol (2014) 0.75
Plasma Exchange for Urgent Apixaban Reversal in a Case of Hemorrhagic Tamponade after Pacemaker Implantation. Tex Heart Inst J (2015) 0.75
Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting. Anesth Analg (2016) 0.75
eComment. Anticoagulation after intracranial haemorrhage in patients with a high risk of thrombosis. Interact Cardiovasc Thorac Surg (2013) 0.75
Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians. Emerg Med Int (2016) 0.75
Effectiveness of prothrombin complex concentrate (PCC) in neonates and infants with bleeding or risk of bleeding: a systematic review and meta-analysis. Eur J Pediatr (2017) 0.75
Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. J Thromb Thrombolysis (2017) 0.75
Is Coagulopathy an Appropriate Therapeutic Target During Critical Illness Such as Trauma or Sepsis? Shock (2017) 0.75
Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. Curr Opin Hematol (2017) 0.75
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA (2003) 4.13
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.75
Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol (2006) 3.03
Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust (2004) 2.74
Management of bleeding following major trauma: a European guideline. Crit Care (2007) 2.40
Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol (2008) 2.27
Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost (2008) 1.81
Guidelines on oral anticoagulation: third edition. Br J Haematol (1998) 1.80
Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol (2002) 1.71
Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol (2001) 1.60
Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke (1992) 1.48
Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost (1997) 1.41
Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care (2008) 1.39
Warfarin reversal. J Clin Pathol (2004) 1.33
Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion. Vox Sang (2005) 1.31
Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med (2007) 1.20
Anticoagulants and their reversal. Transfus Med Rev (2007) 1.18
Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion (2009) 1.17
Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg (2000) 1.13
Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost (2006) 1.11
Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus (2009) 1.05
Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost (2007) 1.04
Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology (2008) 1.03
Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. Ann Hematol (2009) 1.02
Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract (2008) 0.99
Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis (2010) 0.99
Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol (2003) 0.98
Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study. Blood Coagul Fibrinolysis (2007) 0.98
Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal. Br Med J (1976) 0.97
Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia (2000) 0.97
Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res (2006) 0.94
Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res (1999) 0.92
Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med (1999) 0.92
Recombinant factor VIIa. An update on its clinical use. Thromb Haemost (2005) 0.91
Optimisation of the prothrombin complex concentrate dose for warfarin reversal. Thromb Res (2005) 0.91
Prothrombin complex concentrates for urgent anticoagulation reversal in patients with intracranial haemorrhage. Pathophysiol Haemost Thromb (2009) 0.89
Prophylaxis of bleeding episodes and surgical interventions in patients with rare inherited coagulation disorders. Blood Transfus (2008) 0.89
Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. Crit Care (2009) 0.86
Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res (1999) 0.86
Plasma and plasma products in the treatment of massive haemorrhage. Best Pract Res Clin Haematol (2006) 0.82
[Nanofiltration in production of Beriplex P/N: increasing the capacity of virus elimination while maintaining product quality]. Beitr Infusionsther Transfusionsmed (1996) 0.81
Do clinicians decide relying primarily on Bayesians principles or on Gestalt perception? Some pearls and pitfalls of Gestalt perception in medicine. Intern Emerg Med (2014) 3.93
Acquired factor VIII inhibitors. Blood (2008) 2.67
Biochemical markers of muscular damage. Clin Chem Lab Med (2010) 2.25
NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) (2008) 2.23
Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med (2010) 2.20
Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care (2007) 2.09
Circulating microRNAs (miRs) for diagnosing acute myocardial infarction: meta-analysis of available studies. Int J Cardiol (2012) 2.07
N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int (2007) 2.03
The order of draw: myth or science? Clin Chem Lab Med (2013) 1.66
The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med (2011) 1.65
Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department. Clin Chem Lab Med (2013) 1.63
Red blood cell distribution width is significantly associated with aging and gender. Clin Chem Lab Med (2014) 1.58
Preanalytical phase--a continuous challenge for laboratory professionals. Biochem Med (Zagreb) (2012) 1.56
Development of a novel, hemolysis-resistant reagent for assessment of α-amylase in biological fluids. Clin Chem Lab Med (2013) 1.54
Laboratory medicine does matter in science (and medicine)… yet many seem to ignore it. Clin Chem Lab Med (2015) 1.53
Biomedical research platforms and their influence on article submissions and journal rankings: an update. Biochem Med (Zagreb) (2012) 1.53
Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol (2008) 1.50
Postoperative variation of C-reactive protein and procalcitonin in patients with gastrointestinal cancer. Clin Lab (2009) 1.49
Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis (2011) 1.47
Should women with abnormal serum thyroid stimulating hormone undergo screening for anemia? Arch Pathol Lab Med (2008) 1.45
Together we care: new challenges for global haemophilia treatment centers. Indian J Med Res (2009) 1.44
Red blood cell distribution width: A simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci (2014) 1.44
New ways to deal with known preanalytical issues: use of transilluminator instead of tourniquet for easing vein access and eliminating stasis on clinical biochemistry. Biochem Med (Zagreb) (2011) 1.43
Iron and thrombosis. Ann Hematol (2007) 1.43
The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension (2008) 1.42
The role of red blood cell distribution width in cardiovascular and thrombotic disorders. Clin Chem Lab Med (2011) 1.42
The baseline serum value of α-amylase is a significant predictor of distance running performance. Clin Chem Lab Med (2015) 1.42
Reliability of the thrombin-generation assay in frozen-thawed platelet-rich plasma. Clin Chem (2006) 1.40
The health risks of acute exercise should also matter to internal medicine. Eur J Intern Med (2011) 1.40
Is laboratory medicine a dying profession? Blessed are those who have not seen and yet have believed. Clin Biochem (2010) 1.40
Reduction of unsuitable specimens: a more radical and comprehensive approach is needed. Clin Chim Acta (2010) 1.39
Preanalytical quality improvement. In pursuit of harmony, on behalf of European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working group for Preanalytical Phase (WG-PRE). Clin Chem Lab Med (2015) 1.39
The growing impact of publications in haemostasis and thrombosis journals. Thromb Haemost (2007) 1.38
Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes. J Diabetes (2012) 1.31
Survey of national guidelines, education and training on phlebotomy in 28 European countries: an original report by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) working group for the preanalytical phase (WG-PA). Clin Chem Lab Med (2013) 1.31
Vitamin D, thrombosis, and hemostasis: more than skin deep. Semin Thromb Hemost (2012) 1.28
The role of ethnicity, age and gender in venous thromboembolism. J Thromb Thrombolysis (2010) 1.24
Biological variation and reference change values: an essential piece of the puzzle of laboratory testing. Clin Chem Lab Med (2012) 1.22
Mean platelet volume increases with aging in a large population study. Thromb Res (2012) 1.20
The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal (2009) 1.20
ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Rev Clin Lab Sci (2012) 1.20
Impact of the phlebotomy training based on CLSI/NCCLS H03-a6 - procedures for the collection of diagnostic blood specimens by venipuncture. Biochem Med (Zagreb) (2012) 1.20
Acquired factor VIII inhibitors in oncohematology: a systematic review. Crit Rev Oncol Hematol (2008) 1.19
Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta (2008) 1.19
Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus (2011) 1.17
The latest generation of troponin immunoassays: the "cholesterol" of the third millennium? J Am Coll Cardiol (2014) 1.16
Preanalytical management: serum vacuum tubes validation for routine clinical chemistry. Biochem Med (Zagreb) (2012) 1.14
Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol (2010) 1.14
Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J (2007) 1.13
Acquired von Willebrand syndrome: an update. Am J Hematol (2007) 1.13
Different manufacturers of syringes: a new source of variability in blood gas, acid-base balance and related laboratory test? Clin Biochem (2012) 1.13
Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol (2008) 1.12
Smoking-related mortality in the United States. N Engl J Med (2013) 1.12
Compliance of blood sampling procedures with the CLSI H3-A6 guidelines: An observational study by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) working group for the preanalytical phase (WG-PRE). Clin Chem Lab Med (2015) 1.11
Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J (2006) 1.10
A comparative study on the reliability of an automated system for the evaluation of cell-based indirect immunofluorescence. Autoimmun Rev (2012) 1.10
Other advantages to aerobic exercise. CMAJ (2005) 1.10
Improving diagnosis and reducing diagnostic errors: the next frontier of laboratory medicine. Clin Chem Lab Med (2016) 1.09
The clinical and economic burden of drawing blood through intravenous catheters. J Emerg Nurs (2013) 1.08
Relationship between serum vitamin D and inflammatory markers in the general population: comment on the article by Patel et al. Arthritis Rheum (2008) 1.08
Overview on self-monitoring of blood glucose. Clin Chim Acta (2009) 1.08
Preanalytic error tracking in a laboratory medicine department: results of a 1-year experience. Clin Chem (2006) 1.07
Choosing troponin immunoassays in a world of limited resources. J Am Coll Cardiol (2013) 1.06
Assay characteristics and diagnostic improvement from contemporary to high-sensitivity troponin I immunoassays. Am J Med (2013) 1.06
Relation between regular aerobic physical exercise and inflammatory markers. Am J Cardiol (2002) 1.06
Routine noninvasive testing and highly sensitive troponin immunoassays. JAMA Intern Med (2013) 1.06
Drug-induced anti-factor VIII antibodies: a systematic review. Med Sci Monit (2007) 1.06
Urgent monitoring of dabigatran plasma levels: sometimes less is more. Pol Arch Med Wewn (2014) 1.05
Neutrophil gelatinase-associated lipocalin (NGAL), neutrophils, and CKD: which comes first? Am J Kidney Dis (2013) 1.05
Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients. Clin Endocrinol (Oxf) (2007) 1.05
Inherited thrombophilia. Crit Rev Clin Lab Sci (2006) 1.03
Influence of a regular, standardized meal on clinical chemistry analytes. Ann Lab Med (2012) 1.02
Factor V Leiden and hemophilia. Thromb Res (2009) 1.02
EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact. Clin Chem Lab Med (2012) 1.02
Laboratory networking and sample quality: a still relevant issue for patient safety. Clin Chem Lab Med (2012) 1.00
Laboratory investigation of thrombophilia: the good, the bad, and the ugly. Semin Thromb Hemost (2009) 1.00
Letter by Lippi and Cervellin regarding article, "High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease". Circulation (2013) 0.99
Obstructive sleep apnea syndrome and cardiovascular diseases. Semin Thromb Hemost (2011) 0.99
Effects of vigorous mixing of blood vacuum tubes on laboratory test results. Clin Biochem (2012) 0.99
Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal (2009) 0.99
The effective reduction of tourniquet application time after minor modification of the CLSI H03-A6 blood collection procedure. Biochem Med (Zagreb) (2013) 0.98
New scenarios in antidoping research. Clin Chem (2003) 0.98
Circadian variation within hemostasis: an underrecognized link between biology and disease? Semin Thromb Hemost (2009) 0.98
Prostate-specific antigen for prostate cancer screening: a different strategy should be planned. JAMA Intern Med (2013) 0.98
Laboratory applications for smartphones: risk or opportunity? Clin Biochem (2011) 0.98
The metabolic syndrome and the risk of arterial and venous thrombosis. Thromb Res (2007) 0.98
The role of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes. Clin Chem Lab Med (2007) 0.98
Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother (2008) 0.98
The intriguing relationship between the ABO blood group, cardiovascular disease, and cancer. BMC Med (2015) 0.97
The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost (2006) 0.97
The role of osteoprotegerin in cardiovascular disease. Ann Med (2012) 0.97
Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis (2007) 0.96
Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia? Int J Cardiol (2006) 0.96
Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. Nephrol Dial Transplant (2008) 0.96
Von Willebrand factor and thrombosis. Ann Hematol (2006) 0.96
The effect of iron depletion on chronic hepatitis C virus infection. Hepatol Int (2008) 0.96
Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost (2012) 0.96
Neutrophil gelatinase-associated lipocalin in cancer. Adv Clin Chem (2014) 0.96
The role of resistin in colorectal cancer. Clin Chim Acta (2012) 0.95
Acute kidney injury: time to shift from creatinine to the estimated glomerular filtration rate? Crit Care (2008) 0.95